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Introduction: Lung cancer is a leading cause of death in the United
States and among veterans. This study compares patterns of diag-
nosis, treatment, and survival for veterans diagnosed with non-small
cell lung cancer (NSCLC) using a recently established cancer
registry for the Veterans Affairs Pacific Northwest Network with the
Puget Sound Surveillance, Epidemiology, and End Results cancer
registry.
Methods: A cohort of 1715 veterans with NSCLC were diagnosed
between 2000 and 2006, and 7864 men were diagnosed in Wash-
ington State during the same period. Demographics, tumor charac-
teristics, initial surgical patterns, and survival across the two regis-
tries were evaluated.
Results: Veterans were more likely to be diagnosed with stage I or
II disease (32.8%) compared with the surrounding community
(21.5%, p  0.001). Surgical resection rates were similar for
veterans (70.2%) and nonveterans (71.2%) older than 65 years with
early-stage disease (p  0.298). However, veterans younger than 65
years with early-stage disease were less likely to undergo surgical
resection (83.3% versus 91.5%, p  0.003). Because there were
fewer late-stage patients among veterans, overall survival was bet-
ter, although within each stage group veterans experienced worse
survival compared with community patients. The largest differences
were among early-stage patients with 44.6% 5-year survival for
veterans compared with 57.4% for nonveterans (p  0.004).
Conclusions: The use of surgical resection among younger veterans
with NSCLC may be lower compared with the surrounding com-
munity and may be contributing to poorer survival. Cancer quality of
care studies have primarily focused on patients older than 65 years
using Medicare claims; however, efforts to examine care for
younger patients within and outside the Department of Veterans
Affairs are needed.
Key Words: Lung cancer, Surgical resection, Survival, Veterans
Health Administration, Surveillance, Epidemiology, and End results
(SEER).
(J Thorac Oncol. 2011;6: 1726–1732)
Lung cancer is the leading cause of cancer-related death inthe United States and the leading cause of cancer deaths
for veterans cared for by the U.S. Veterans Health Adminis-
tration (VHA).1 The burden of lung cancer among veterans is
nearly double compared with the general population because
of the high prevalence of smoking among military service
members.2–4 There is relatively little information on quality
and patterns of care for patients treated within the Veterans
Affairs (VA) for non-small cell lung cancer (NSCLC).5 A
historical study observed that lung cancer resection rates for
early-stage disease were lower among VA patients compared
with national rates, potentially because of difficulty accessing
specialty care.6 In 2006, the VA conducted a chart review at 132
facilities randomly selecting 20 patients with lung cancer from
each site,7 observing that only 46% of patients who underwent
surgery were treated within the recommended timeframe of 8
weeks.8 Disparity in initial treatment, particularly surgery for
early-stage disease, is a key priority both within and outside of
the VA as black race, lower education, and lower socioeconomic
status have been observed to be associated with low rates of
surgical resection for early-stage lung cancer.9–11
In 1995, as part of the VHA’s transformation from a
highly centralized hospital system to a multifaceted primary
and specialty care-based delivery system,12 the VHA devel-
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oped a comprehensive oncology program that included a
mandate for a national cancer registry program to evaluate
and improve the quality of oncology care delivered to veter-
ans.13 In 2010, there were 132 cancer registry programs in the
VHA that comprise the VA Central Cancer Registry of which
eight comprise the Northwest Veterans Affairs Oncology
Registry (VAOR) which provided data for this study.
As no previous studies have used regional or national
VA cancer registries to evaluate care for NSCLC, the objec-
tive of this study was first to examine the completeness of the
demographic and tumor characteristic information in North-
west VAOR, and then compare tumor characteristics, surgical
resection patterns, and survival for VA patients with patients
in the surrounding community. We used records from the
Puget Sound Surveillance, Epidemiology, and End Results
(SEER) registry, one of the oldest SEER registries in the
nation, to serve as the gold standard for our comparison.14
PATIENTS AND METHODS
Subjects
We identified subjects in both the VAOR and Puget
Sound SEER registries who were diagnosed with NSCLC
between January 1, 2000, and December 31, 2006. Using the
VAOR SQL database, all patients with an International Clas-
sification of Diseases, Ninth Revision diagnosis code of 162
were identified. Patients younger than 18 years or older than
100 years were excluded, as were cases identified as diag-
nosed only on the death certificate or at the time of autopsy.
Women were excluded from both VAOR and SEER data-
bases. Although women comprise 47% of SEER subjects,
only approximately 3% of lung cancer cases in the VA are
among women, thus because of privacy concerns associated
with potential of identifiability in subgroup analyses, they
were excluded. Histologies for NSCLC were classified as
adenocarcinoma, squamous cell carcinoma, other NSCLC
(including bronchioloalveolar carcinoma, large-cell carci-
noma, mixed histology, and other histologies), and NSCLC
not otherwise specified.15
Registry Data
SEER collects and publishes cancer incidence and sur-
vival data from 17 distinct population-based cancer registries
covering approximately 26% of the US population, and the
completeness and accuracy of data collection in SEER have
been extensively validated.14,16 SEER data include informa-
tion on patient demographics, tumor morphology and stage at
diagnosis, first course of treatment, and follow-up for vital
status.17,18 SEER records were obtained for this study based
on the November 2008 submission public use file.19 Similar
to SEER, registries contributing to the VAOR perform ac-
cession, abstraction, and follow-up activities in conformity
with American College of Surgeons and Commission on
Cancer data collection standards.20 All VA cancer registries
are required to have dedicated tumor registrars and use
automated registries using uniform software. The recom-
mended registrar staffing ratio is 1 full-time equivalent posi-
tion per 350 new cancer cases per year. The VA registrar
ensures completeness of registry data by contacting non-VA
physicians as well as patients and family members, if neces-
sary, to ensure completeness of documentation for patients
diagnosed in the VA who may receive a portion of their initial
care outside of the VA. The VA is not a closed system, and
it is possible that some subjects were diagnosed in both the
VA and an outside hospital in the Puget Sound SEER catch-
ment area. Privacy issues precluded direct identification of
duplicate subjects, and based on use agreements with SEER,
no attempt was made to identify duplicates.21
The staging system used in both SEER and VAOR
databases is based on the Revised International System for
Staging Lung Cancer 6th edition, as adopted by the American
Joint Committee on Cancer.22 This staging system, based on
tumor, node, metastasis classification, is a measure of the
extent of disease, can determine prognosis, and can guide
management. This information is incorporated into the over-
all disease stage (stages I–IV).22 For both the SEER and
VAOR databases, the extent of disease was evaluated based
on clinical-diagnostic stage. Both registries include patho-
logic information when available. However, because prac-
tices may differ between providers in the community and VA
that would influence availability of pathologic staging infor-
mation, the main comparison was based on clinical stage.
This variable includes information pertaining to medical
history, physical examination, laboratory testing, radiology,
tissue sampling, and other treatment evaluation undertaken
before primary therapy.
Survival estimates were based on time to all-cause
mortality. The Puget Sound SEER registry uses a variety of
methods to collect vital status follow-up information, primar-
ily linking to death certificate files from the Washington State
Department of Health and to records from Washington State
Department of Motor Vehicles. In addition, records of sub-
jects not known to be deceased are submitted to the Center for
Medicare/Medicaid Services and the Social Security Admin-
istration Death Master File to determine if benefits are being
collected and searches using the National Death Index and
commercial services including Accurint. VA cancer registrars
identify deceased veterans through death certificates internal
to the VHA and identification of deaths from other VA
benefit programs including pension and burial programs.
Similar to SEER, VA routinely exchanges information about
deceased individuals with the Center for Medicare/Medicaid
Services and the Social Security Administration Death Mas-
ter File.23
Analysis
Descriptive statistics were used to compare race (white
or non-white), age at initial diagnosis (55, 55–64, 65–74,
75–84, and 85), receipt of surgery, tumor stage (I, II, III,
IV, or unknown), and histologic subtype. All variables were
treated categorically, and 2 tests were used to compare
veterans in VAOR with subjects in SEER. Kaplan-Meier
estimates of survival from the date of diagnosis were based
on the log-rank test. All subjects not known to be deceased
were censored at the time of the last follow-up for each
database, which was the end of 2006 for SEER and the end of
2008 for VAOR.19 Analyses were stratified by age, younger
than 65 years and 65 years and older. Kaplan-Meier survival
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curves were plotted for patients younger than 65 years and 65
years and older for all stages and for stage I and II subjects
who underwent surgery. To further adjust for age differences
in the receipt of surgery, a logistic regression model was used
including age as an adjustment variable. The results are
presented as age-adjusted p values in the table. Proportional
hazards models were used to further adjust survival estimates
by age for both the overall and age-stratified analyses. The
age-adjusted p values are presented. The proportional hazards
assumption was evaluated using log-log plots of survival
curves. We note that the racial distribution was similar
between the two registries and that other covariates, such as
comorbidity and body mass index, are only available through
linkage to medical claims. Thus, further adjustment for co-
morbidity or other health factors was not feasible. All anal-
yses were conducted in Stata 11.1. This study was reviewed
and approved by the Institutional Review Board at VA Puget
Sound Health Care System.
RESULTS
Ten patients were excluded because their age at
diagnosis was less than 18 years or more than 100 years,
and 394 subjects were excluded based on the tumor being
identified at autopsy or death certificate only. The final
sample size included 1715 male veterans in the VAOR and
7864 men diagnosed with lung cancer in the Puget Sound
SEER registry.
The mean age was 68.0 years (SD  9.6) for the 1715
veterans and 69.3 years (SD  11.0) for the 7864 men
identified in the Puget Sound SEER registry. Tumor charac-
teristics are presented in Table 1. The proportion of patients
diagnosed with stage IV disease was similar in both regis-
tries, 37.0% in VAOR and 39.0% in SEER (p  0.121).
However, the proportion of subjects in SEER with missing
stage information was 12.2% compared with 5.4% in VAOR.
The VAOR population was younger, with 73% of VA pa-
tients younger than 75 years at the time of diagnosis com-
pared with 64% of SEER patients. The majority of patients in
both registries were white, reflecting the demographics of this
age group in the Pacific Northwest.
The frequency of surgery is presented in Table 2. Stage
I and II patients in the VAOR younger than 65 years were less
likely to undergo surgery (83.3%) compared with stage I and
II patients younger than 65 years in SEER (91.5%, age-
adjusted p 0.003). There were no differences in surgery for
stage I and II patients aged 65 years and older (age-adjusted
p  0.298). For younger patients with stage III disease,
surgery rates were similar for veterans and nonveterans (age-
adjusted p  0.423), whereas there was a trend toward more
frequent surgical resection among older veterans with stage
III disease (age-adjusted p  0.001).
As presented in Table 2, overall survival was similar
for younger patients in VAOR and SEER when all stages
were combined (including missing stage), with nearly over-
lapping survival curves (Figure 1). For patients younger than
65 years, 5-year survival for all stages combined was 16.0%
in VAOR and 17.9% in SEER (age-adjusted p  0.415).
Similarly, among patients aged 65 years and older, 5-year
survival was similar for veterans and nonveterans (age-ad-
justed p  0.142). We note the unadjusted survival propor-
tions of 13.5% for veterans and 10.9% for nonveterans reflect
the lower frequency of veterans older than 75 years. Adjust-
ing for age affected the significance of the results for the more
than 65 cohorts, whereas age adjustment did not change the
findings substantially for the younger cohort.
Survival for stage I and II patients was considerably
lower (44.6%) for VAOR patients younger than 65 years
compared with 57.4% for the SEER cohort (age-adjusted p
0.004). Similarly, survival for stage I and II patients was
slightly lower for VAOR patients older than 65 years (age-
adjusted p value  0.035). The combined survival outcomes
for stage I and II patients include a mixture of patients who
did and did not undergo surgery. The largest differences in
survival between VAOR and SEER were observed among
patients who did not undergo resection. Among stage I and II
patients who underwent surgery, there was a slight trend of
worse survival for VAOR patients overall (age-adjusted p
value  0.060; Figure 2). However, the differences in sur-
vival between VAOR and SEER were more pronounced
among stage I and II patients who did not undergo surgery
(age-adjusted p value  0.015; Figure 3). Notably, survival
was considerably lower among stage I and II patients who did
not undergo surgery in both VAOR and SEER, with few
patients surviving beyond 5 years.
TABLE 1. Comparison of Demographic and Tumor
Characteristics among Subjects with Non-small Cell Lung
Cancer in VAOR and SEER Registries
VAOR
(N  1715),
N (%)
SEER
(N  7864),
N (%) p
Age (yr) 0.001
55 168 (9.8) 797 (10.1)
55–64 484 (28.2) 1722 (21.9)
65–74 601 (35.0) 2521 (32.1)
75–84 430 (25.1) 2317 (29.5)
85 32 (1.9) 507 (6.5)
White 1514 (88.3) 7055 (89.7) 0.080
Histology 0.001
Adenocarcinoma 352 (20.5) 2213 (28.1)
Squamous 456 (26.6) 1711 (21.8)
NSCLC other 119 (6.9) 3006 (38.2)
Not specified 788 (46.0) 934 (11.9)
Year of diagnosis 0.118
2000–2002 696 (40.6) 3402 (43.3)
2003–2004 500 (29.2) 2219 (28.2)
2005–2006 519 (30.3) 2843 (28.5)
Stage 0.001
I 429 (25.0) 1345 (17.1)
II 133 (7.8) 347 (4.4)
III 426 (24.8) 2144 (27.3)
IV 635 (37.0) 3070 (39.0)
Unknown 92 (5.4) 958 (12.2)
VAOR, Veterans Affairs Oncology Registry; SEER, Surveillance, Epidemiology,
and End Results; NSCLC, non-small cell lung cancer.
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DISCUSSION
This initial examination of the Northwest VAOR dem-
onstrates a high level of completeness in capturing tumor
characteristics among veterans newly diagnosed with NSCLC
in a VA medical center. The completeness of key tumor
characteristics, including tumor stage, was higher in the
VAOR than in the Puget Sound SEER registry. The distribu-
tion of NSCLC patients with stage IV disease was similar to
SEER and to the 300,000 subject National Cancer Data-
base.24 These results suggest that the VAOR is a reliable
source of data to examine resource utilization, treatment
heterogeneity, comparative effectiveness, and survival of pa-
FIGURE 1. Survival for patients
with non-small cell lung cancer (all
stages combined) in the VA Oncol-
ogy Registry and Puget Sound
SEER, stratified by age. VA, Veter-
ans Affairs; SEER, Surveillance, Epi-
demiology, and End Results.
FIGURE 2. Survival for patients
with stage I and II non-small cell
lung cancer who underwent surgi-
cal resection in the VA Oncology
Registry and Puget Sound SEER,
stratified by age. VA, Veterans Af-
fairs; SEER, Surveillance, Epidemiol-
ogy, and End Results.
FIGURE 3. Survival for patients
with stage I and II non-small cell
lung cancer who did not undergo
surgical resection in the VA Oncol-
ogy Registry and Puget Sound
SEER, stratified by age. VA, Veter-
ans Affairs; SEER, Surveillance, Epi-
demiology, and End Results.
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tients treated within the Pacific Northwest for NSCLC. We do
note differences in surgical rates for stage I and II patients
compared with stage III patients. Although resection rates
were lower in VAOR for stage I and II patients compared
with SEER, the proportion of veterans with stage III disease
were actually more likely to undergo resection. Although the
difference in the absolute number of stage III patients under-
going surgery between the VAOR and SEER cohort is rela-
tively small, it is possible a portion of these patients may be
understaged at VA Medical Centers compared with non-VA
facilities. Future studies should examine differences in stag-
ing procedures, including positron emission tomography,
between VA and non-VA facilities.
This evaluation also provides the foundation for ensur-
ing the validity of future studies combining VA cancer
registry records with the VA’s comprehensive electronic
medical record databases, similar to the SEER-Medicare
database that combines Medicare claims with SEER records
for patients older than 65 years.25 The VA has invested
heavily in electronic medical records, with all inpatient and
outpatient visits captured since 1986, and databases that now
include comprehensive information including pharmacy re-
cords, vital measures, and laboratory values. Linkage of
cancer registry records with these electronic records provides
a unique resource to examine cancer care and allow for
inclusion of younger men.26 Although SEER-Medicare has
been used extensively to examine cancer care for patients
older than 65 years, few large studies have been able to
include younger patients. The VAOR represents a unique
opportunity to focus examinations on patients seen within a
vertically integrated healthcare delivery system.
Our findings suggest that younger veterans with early-
stage disease were less likely to undergo surgery and have
worse survival compared with men in the surrounding com-
munity. Ensuring that all eligible candidates are offered
surgery is critical for this devastating disease and a key
priority for the VA.27,28 The reason for lower surgery rates in
the VA compared with the community cannot be determined
based on these data, as no claims or comorbidity records are
available for the SEER population. The significantly worse
overall survival among younger veterans who did not un-
dergo surgery compared with men in the community who did
undergo surgery (Figure 2) suggests that comorbidities may
be higher among veterans in this population and may have
been a factor in the lower surgery rates. The VA recently
conducted a chart review of 20 patients with lung cancer from
132 medical centers across the VA. This study observed that
veterans with early-stage disease had longer time in initiating
treatment from the time of diagnosis compared with ad-
vanced-stage patients.29 One of the potential reasons for the
delays was access to appropriate surgeons, which may also be
contributing to lower rates of surgery in the VA compared
with the community.
This comparison is unique as few studies have com-
pared cancer survival for veterans and nonveterans. Regula-
tions prohibiting the exchange of cancer registry data among
VA and non-VA registries in the last decade have made such
comparisons difficult. One historical study from Pennsylva-
nia observed that survival was worse for white veterans
compared with whites in the community, whereas survival for
black veterans was similar to blacks in the community.30 Our
results suggest that these comparisons are important to be
able to compare healthcare delivery between different sys-
tems of care, and facilitation of data sharing between federal
and nonfederal agencies should be encouraged.
A key limitation of this study is the lack of covariates to
control for potential differences between the VAOR and SEER
population among patients younger than 65 years. Although
detailed comorbidity, smoking history, body mass index, pul-
monary function tests, laboratory tests, and other information are
available on the veteran population, similar information was not
available for the SEER cohort. We note that the VAOR and
SEER populations differed considerably in the distribution of
patients older than 75 years. Because of the lack of comor-
bidity and other key variables, results are presented stratified
by age with additional age adjustment to estimate appropriate
p-values. Although this did not change the results for patients
younger than 65 years, for patients 65 years and older, we
observed significant differences in unadjusted and age-ad-
justed analyses. After age adjustment, survival among older
patients was similar in both registries.
Another limitation is the lack of information on treat-
ment other than surgery. One unique future opportunity of the
VAOR will be the ability to examine outcomes associated
with detailed chemotherapy patterns as VA databases include
chemotherapy dose and laboratory measures to evaluate re-
sponse and toxicities. Similar data were not available in other
registry settings, including SEER-Medicare, which only has
the date of chemotherapy claim.25 Our findings cannot be
generalized to female veterans. Within the next decade,
women are expected to comprise 10% of the VA population.
However, the population in this study where the mean age
was 68 years includes less than 3% women. Although all VA
cancer registries use standardized cancer registry software
and have access to similar electronic medical record systems,
the completeness and validity of data observed in this study
may not exist across all VA registries nationally. In addition,
some VA patients may have been included in the SEER
registry counts. The overall number of subjects is likely to be
minimal as VA stopped reporting to SEER in 2005, and
SEER typically excludes patients diagnosed at VA hospi-
tals.21 Privacy constraints precluded identification of diagnos-
ing facility for verification, and individual identifiers were not
available to examine subjects with overlapping data.
Overall, this initial evaluation demonstrates the validity
of VAOR and highlights the importance of this resource for
evaluating and improving oncology care for veterans. The
gap identified in use of surgical resection for younger, early-
stage patients in the VA is a critical area for oncology
programs in the VA’s Northwest network to further ensure
that no true disparity exists.
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